Pharma counsel still wary of non-traditional TMs despite benefits

Counsel at pharmaceutical companies say non-traditional marks can play an important role in portfolio management, but that regulatory concerns remain
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: